AaronLeeBosterMD

Neurology • Columbus, OH

Neuroimmunology/Multiple Sclerosis

Systems Medical Chief, Neuroimmunology

Join to view full profile

Dr. Boster is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boster's full profile

Already have an account?

Office
8000 Ravines Edge Ct
Ste 200
Columbus, OH 43235
Phone+1 614-304-3444

Fax+1 614-304-3433

Education & Training

University of MichiganResidency, Neurology, 2003 - 2006
University of MichiganInternship, Internal Medicine, 2002 - 2003
University of Cincinnati College of MedicineClass of 2002

Certifications & Licensure

IL State Medical License 2023 - 2026
MI State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
WV State Medical License 2023 - 2026
IN State Medical License 2023 - 2025
KY State Medical License 2023 - 2025
OH State Medical License 2008 - 2025
TN State Medical License 2023 - 2025
TX State Medical License 2023 - 2025
WI State Medical License 2023 - 2025
AL State Medical License 2023 - 2024
American Board of Psychiatry and Neurology Neurology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Combination Therapy Using Cellcept and Rebif in RRMS Start of enrollment: 2006 Aug 01
Completed
Early Phase 1
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis Start of enrollment: 2011 Mar 01
Completed
Phase 3
Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump Start of enrollment: 2012 Dec 01
Completed
Phase 3
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Start of enrollment: 2013 Nov 01
Completed
Phase 2
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy Start of enrollment: 2014 Jan 01
Withdrawn
Phase 4
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

13 citations
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass
Multiple Sclerosis. 2022-04-01
33 citations
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial:
Alasdair Coles, Douglas L. Arnold, Ann D Bass, Aaron Boster, D Alastair S Compston
Therapeutic Advances in Neurological Disorders. 2021-04-23
13 citations
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
Ann D Bass, Rafael Arroyo, Aaron Boster, Alexey Boyko, Sara Eichau
Multiple Sclerosis and Related Disorders. 2021-04-01

Press Mentions

Diagnosing MS During a Pandemic: UK vs. USOctober 23rd, 2020
Neurologists Turn to Telemedicine During Coronavirus ShelteringApril 3rd, 2020
Hospital Plots Leadership Path in MS ResearchSeptember 8th, 2019
Join now to see all